home / stock / irclf / irclf news


IRCLF News and Press, Intercure Ltd From 04/03/23

Stock Information

Company Name: Intercure Ltd
Stock Symbol: IRCLF
Market: OTC

Menu

IRCLF IRCLF Quote IRCLF Short IRCLF News IRCLF Articles IRCLF Message Board
Get IRCLF Alerts

News, Short Squeeze, Breakout and More Instantly...

IRCLF - InterCure Reschedules 2022 Full Year Results Conference Call

NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) announced today that it has rescheduled its previously announced conference call to discuss the c...

IRCLF - InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results

Record fiscal year 202 2 revenue of $ 150 million Record fiscal year 202 2 Adjusted EBITDA * of $ 3 2 million Record fiscal year 202 2 net income of $ 17 million Generated $20 Million cas...

IRCLF - InterCure Files Lawsuit Against Cann Pharmaceuticals to Recover Funds Following Failed Merger

NEW YORK, TORONTO, and HERZLIYA, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(“ InterCure ” or the “ Company ”) the biggest and most profitable cannabis company outside of north America, announ...

IRCLF - InterCure Announces the Termination of its Acquisition Agreement with Cann Pharmaceutical (dba Better)

NEW YORK and TORONTO and HERZLIYA, Israel, Feb. 01, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) (" InterCure " or the " Company ") announces that, further to the merger agreement with Cann Pharmaceutical Ltd. (“ Better ...

IRCLF - InterCure: True International Cannabis Play

InterCure offers a pure play on the European cannabis market with a focus on Israel. The company went public via a SPAC in April and now trades below the PIPE price at only $8. The stock is cheap at only 2x EV/'22 sales targets. For further details see: InterCure: True I...

IRCLF - InterCure reports Q1 results

InterCure (IRCLF): Q1 Revenue of NIS 33.1M (+677.0% Y/Y)Positive cash flow from operations for the third consecutive quarter of NIS 8MEBITDA of NIS 9.5MShares +2.52%.Press Release For further details see: InterCure reports Q1 results

IRCLF - This SPAC Allows You to Invest in the Booming Israeli Cannabis Market

Today, Canada's cannabis companies are the only ones that trade on U.S. exchanges, but their businesses have struggled amid rampant oversupply. While U.S. cannabis companies are performing much better financially than their Canadian counterparts, their business is still illegal at the feder...

IRCLF - No Reason To Invest In The Ark Israel Fund When You Can Invest In ARKK Or ARKQ

The ARK Invest Israel Innovation Technology ETF focuses on a single country that is, in and of itself, somewhat of a disruptive technology incubator. As you might expect, IZRL has been punched-in-the nose by the market rotation out of tech and into value, and is down 18% from its high...

IRCLF - CannabisNewsBreaks - technical420 Highlights Five Emerging Must-Watch Cannabis Markets

A recent editorial by Anthony Varrell of technical420 reviews five emerging cannabis markets suggested as “need-to-watch” for investors in 2020.  These include Colombia, Uruguay, Australia, Israel and China.  The publication also highlights companies that are laser-focu...

IRCLF - INTERCURE: CANNDOC Initiates Phase 3 Clinical Trial Evaluating Pharma Grade Medicinal Cannabis (CANNDOC T1/C20) For Children With Autism Spectrum Disorder

HERZLIYA, Israel , Nov. 21, 2019 /PRNewswire/ -- Israeli medical cannabis company  InterCure Ltd.  (TASE: INCR) announced that its wholly-owned subsidiary  Canndoc  initiated a phase 3 clinical trial with the Shamir Medical Center ( Assaf HaRofeh ) f...

Previous 10 Next 10